ATE470445T1 - Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads) - Google Patents

Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads)

Info

Publication number
ATE470445T1
ATE470445T1 AT08004276T AT08004276T ATE470445T1 AT E470445 T1 ATE470445 T1 AT E470445T1 AT 08004276 T AT08004276 T AT 08004276T AT 08004276 T AT08004276 T AT 08004276T AT E470445 T1 ATE470445 T1 AT E470445T1
Authority
AT
Austria
Prior art keywords
ranolazine
eads
depolarization
medication
produce
Prior art date
Application number
AT08004276T
Other languages
German (de)
English (en)
Inventor
Luiz Belardinelli
Charles Antzelevitch
Brent Blackburn
Original Assignee
Gilead Palo Alto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Palo Alto Inc filed Critical Gilead Palo Alto Inc
Application granted granted Critical
Publication of ATE470445T1 publication Critical patent/ATE470445T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT08004276T 2002-04-04 2003-04-04 Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads) ATE470445T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37015002P 2002-04-04 2002-04-04
US40829202P 2002-09-05 2002-09-05
US42258902P 2002-10-30 2002-10-30

Publications (1)

Publication Number Publication Date
ATE470445T1 true ATE470445T1 (de) 2010-06-15

Family

ID=29255318

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08004276T ATE470445T1 (de) 2002-04-04 2003-04-04 Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads)
AT03723907T ATE397932T1 (de) 2002-04-04 2003-04-04 Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03723907T ATE397932T1 (de) 2002-04-04 2003-04-04 Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien

Country Status (19)

Country Link
US (2) US20030220344A1 (enExample)
EP (3) EP1930007B1 (enExample)
JP (1) JP4608217B2 (enExample)
KR (2) KR20040099395A (enExample)
CN (2) CN101843619A (enExample)
AT (2) ATE470445T1 (enExample)
AU (3) AU2003230810B2 (enExample)
CA (1) CA2481192C (enExample)
CY (1) CY1110400T1 (enExample)
DE (2) DE60332975D1 (enExample)
DK (2) DK1490066T3 (enExample)
ES (2) ES2304507T3 (enExample)
IL (1) IL197406A0 (enExample)
MX (1) MXPA04009637A (enExample)
NO (1) NO330953B1 (enExample)
NZ (1) NZ535610A (enExample)
PT (2) PT1490066E (enExample)
SI (2) SI1490066T1 (enExample)
WO (1) WO2003086401A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
NZ536678A (en) * 2002-05-21 2007-01-26 Cv Therapeutics Inc Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
WO2005061470A1 (en) * 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
US20060111361A1 (en) * 2004-11-09 2006-05-25 Brent Blackburn Method of reversing left ventricle remodeling
RU2384332C2 (ru) * 2005-01-06 2010-03-20 Си Ви Терапьютикс, Инк. Фармацевтические препаративные формы замедленного высвобождения
US20060263427A1 (en) * 2005-05-03 2006-11-23 Roberts Richard H Quinine formulations
US20080153840A1 (en) * 2006-12-21 2008-06-26 Luiz Belardinelli Reduction of cardiovascular symptoms
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
JP2010518170A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 冠微小血管疾患の処置のためのラノラジンの使用
EP2117509A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of cardiovascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
ES2402675T3 (es) * 2007-05-31 2013-05-07 Gilead Palo Alto, Inc. Ranolazina para el péptido natriurético de tipo cerebral a niveles elevados
CN101977605A (zh) * 2008-02-06 2011-02-16 吉利德科学股份有限公司 雷诺嗪治疗疼痛的用途
CA2735653A1 (en) * 2008-09-04 2010-03-11 Gilead Sciences, Inc. Method of treating atrial fibrillation
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
CA2761771A1 (en) * 2009-05-14 2010-11-18 Gilead Sciences, Inc. Ranolazine for the treatment of cns disorders
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
JP2015519333A (ja) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
CA2873093A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013175357A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9765020B2 (en) 2012-05-23 2017-09-19 Cellix Bio Private Limited Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis
CA2873098A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014027262A2 (en) * 2012-08-14 2014-02-20 Mahesh Kandula Compositions and methods for the treatment angina and cardiovascular conditions
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
WO2014037834A2 (en) 2012-09-08 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
AU2014296145A1 (en) * 2013-08-01 2016-01-28 Gilead Sciences, Inc. Compound and methods for treating long QT syndrome
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (en) 2014-09-29 2020-03-18 Cellix Bio Private Limited Compounds and compositions for the treatment of multiple sclerosis
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法
KR101617683B1 (ko) 2015-01-09 2016-05-03 연세대학교 산학협력단 부정맥 치료제 효과 평가 시스템 및 방법
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
CN116808039A (zh) * 2023-03-27 2023-09-29 河南中医药大学第一附属医院 青藤碱在制备钾离子、钠离子通道抑制剂中的应用
WO2025010429A1 (en) * 2023-07-06 2025-01-09 The General Hospital Corporation Method and apparatus for evaluating cardiac function

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
IE80710B1 (en) * 1989-06-23 1998-12-16 Syntex Inc Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult
JPH03141258A (ja) * 1989-10-25 1991-06-17 Kowa Co 新規なピペラジン誘導体
DE69429524T2 (de) * 1993-09-24 2002-08-08 The University Of British Columbia, Vancouver Aminocyclohexylester und ihre anwendung
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
AU778203B2 (en) * 2000-02-18 2004-11-25 Gilead Sciences, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
AU6323001A (en) * 2000-05-19 2001-12-03 Bionebraska Inc Treatment of acute coronary syndrome with glp-1
AU2001277938A1 (en) * 2000-07-21 2002-02-05 Cv Therapeutics, Inc. Method for treating angina
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
PT1930007E (pt) 2010-08-17
US20030220344A1 (en) 2003-11-27
CA2481192A1 (en) 2003-10-23
AU2003230810A1 (en) 2003-10-27
NO330953B1 (no) 2011-08-22
NZ535610A (en) 2006-05-26
EP2198866A1 (en) 2010-06-23
JP2005528393A (ja) 2005-09-22
DE60321550D1 (de) 2008-07-24
SI1930007T1 (sl) 2010-08-31
DK1930007T3 (da) 2010-08-30
EP1930007A1 (en) 2008-06-11
ES2304507T3 (es) 2008-10-16
WO2003086401A1 (en) 2003-10-23
EP1490066B1 (en) 2008-06-11
KR20040099395A (ko) 2004-11-26
EP1930007B1 (en) 2010-06-09
CA2481192C (en) 2012-07-03
CN101843619A (zh) 2010-09-29
CN100548300C (zh) 2009-10-14
AU2009201065A1 (en) 2009-04-09
AU2003230810B2 (en) 2009-02-26
AU2009201065B2 (en) 2011-07-21
HK1120390A1 (en) 2009-04-03
IL197406A0 (en) 2011-07-31
JP4608217B2 (ja) 2011-01-12
US20100004255A1 (en) 2010-01-07
MXPA04009637A (es) 2005-07-14
NO20044783L (no) 2004-11-03
ATE397932T1 (de) 2008-07-15
KR20100119804A (ko) 2010-11-10
PT1490066E (pt) 2008-07-22
SI1490066T1 (sl) 2008-10-31
ES2345573T3 (es) 2010-09-27
AU2011202135A1 (en) 2011-05-26
EP1490066A1 (en) 2004-12-29
CN1646127A (zh) 2005-07-27
DE60332975D1 (de) 2010-07-22
DK1490066T3 (da) 2008-10-13
CY1110400T1 (el) 2015-04-29

Similar Documents

Publication Publication Date Title
ATE470445T1 (de) Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads)
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
Neganova et al. Mechanisms of antioxidant effect of natural sesquiterpene lactone and alkaloid derivatives
DE60222745D1 (de) Verwendung von neurofilamentproteinen zur behandlung von tumoren
NO20011283D0 (no) Anvendelse av integrin-antagonister ved behandling av multippelt myelom og myelom-indusert benresorpsjon
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
ATE451091T1 (de) Kosmetisches peeling-verfahren unter verwendung von harnstoff
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
DE50213170D1 (de) Verwendung eines Mittel zur Therapie der Herzhypertrophie
WO2004044144A3 (en) Methods for inducing regeneration, remyelination, and hypermyelination of nervous tissue
ATE380551T1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
MXPA05011428A (es) Metodo de tratamiento de fibrilacion atrial o trepidacion auricular.
CO5170445A1 (es) Nuevos compuestos morfinoides,su preparacion y utilizacion
DE602004016292D1 (de) Verwendung einer zusammensetzung mit vitamin k1-oxid oder einem derivat daraus zur behandlung und/oder vorbeugung von hautverletzungen bei säugern
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
ATE214923T1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
DE60033633D1 (de) Kit aus polyakrylamidgel zur herstellung einer kapsel im gewebe eines säugetierorganismus und tierischen allogenen oder xenogenen zellen , zur behandlung von onkologischen krankheiten und der diabetes mellitus
ATE127118T1 (de) 2-alkyl-3-benzoylbenzofurane zur behandlung von herzarrhythmia.
RU2002108682A (ru) Способ инактивации патогенных грибов
ATE376914T1 (de) Verwendung einer wässrigen lösung mit einem oder mehreren bifluoriden zur verbesserung des trocknungsprozesses von frischholz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1930007

Country of ref document: EP